Natalizumab
CAS No. 189261-10-7
Natalizumab ( —— )
Catalog No. M23864 CAS No. 189261-10-7
Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 224 | In Stock |
|
5MG | 383 | In Stock |
|
10MG | 615 | In Stock |
|
25MG | 897 | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNatalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNatalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
DescriptionNatalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
Recptorα4β1 integrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number189261-10-7
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3(2):259-68.
molnova catalog
related products
-
RGDS peptide
RGDS peptide (Arg-Gly-Asp-Ser) is a integrin binding sequence that inhibits integrin receptor function, a tetrapeptide analogue of the cell attachment site of fibronectin.
-
Cyclo(-RGDfK) TFA
Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
-
RGD peptide GRGDNP
RGD peptide (GRGDNP) acts as an inhibitor of integrin-ligand interactions and can induce apoptosis in the absence of signals and integrin-mediated cell clustering.